Regeneron Files BLA For VEGF Trap-Eye In Wet AMD; Second Filing Anticipated This Year
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Regeneron Pharmaceuticals Inc. is hoping to launch aflibercept ophthalmic solution in the fall with clinically equivalent trial results and a dosing advantage over Roche 's VEGF inhibitor Lucentis (ranibizumab), the current standard of care for "wet" age-related macular degeneration.
You may also be interested in...
Roche Looks Ahead To 2011, But Avastin Woes And Other Concerns Could Pose Challenges
After several setbacks in 2010, the Swiss Pharma lowers its guidance on its best-selling drug and braces for the results from a key study.
Regeneron/Bayer Announce Positive VEGF Trap-Eye Data In A Second Eye Disease
Application to treat central retinal vein occlusion may be in the works to follow soon after wet AMD filing set for first half of 2011.
Regeneron/Bayer Bullish On Wet-AMD Drug But Commercial Success Is No Guarantee
Positive results of two Phase III studies show VEGF Trap-Eye candidate has potential for dosing every two months, but competing against Roche's Lucentis and off-label Avastin won't be easy.